ABS Summary Statement: Update on optimal duration of adjuvant antihormonal therapy

The guidance from NICE is now dated. Updates are awaited from NICE or the UK Breast Cancer Group on current developments. In the meantime, following a review of all published data, ABS have produced a summary statement to help guide adjuvant hormonal therapy in appropriate patients

Classifications: Adjuvant & Neoadjuvant Treatment

Keywords: Endocrine therapy